NCT05409365

Brief Summary

This study aims to assess the expression of SCCA2 in the skin of patients with warts and to detect its correlation with characteristics of warts.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
50

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started May 2022

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2022

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

June 1, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

June 8, 2022

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2023

Completed
Last Updated

June 10, 2022

Status Verified

June 1, 2022

Enrollment Period

6 months

First QC Date

June 1, 2022

Last Update Submit

June 7, 2022

Conditions

Verruca VulgarisHealthy

Outcome Measures

Primary Outcomes (1)

  • Assessment of Squamous Cell Carcinoma Antigen2 in Verruca Vulgaris

    Immunohistochemical staining: investigators will use monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody). Immunohistochemical staining will be performed the pattern of immunostaining for SCCA2 will be evaluated in both the epidermis and dermis of wart lesions. The immunohistochemical score (IHC) range will be as follows: 0: negative expression of SCCA2; 1+: weak expression of SCCA2; 2+: moderate expression of SCCA2; and 3+: strong expression of SCCA2.

    through study completion, an average of 1 year

Interventions

Immunohistochemical staining monoclonal antibodies to SCCA2 (SERPINB4/ SCCA2 antibody)OTHER

Immunohistochemical staining

Eligibility Criteria

Age1 Year+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

primary care clinic

You may qualify if:

  • Patients present with warts (verruca vulgaris type).

You may not qualify if:

  • Subjects who presenting with allergic diseases or other dermatological diseases or had a history of squamous cell carcinoma will be excluded from this study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, Egypt

RECRUITING

MeSH Terms

Conditions

Warts

Interventions

leupin

Condition Hierarchy (Ancestors)

Papillomavirus InfectionsDNA Virus InfectionsVirus DiseasesInfectionsSkin Diseases, ViralTumor Virus InfectionsSkin Diseases, InfectiousSkin DiseasesSkin and Connective Tissue Diseases

Study Officials

  • Ashraf Ahmed Abd El-Latif Abd El-Latif, Lecturer

    Director

    STUDY DIRECTOR

Central Study Contacts

Fatma Aboelmgd Abd-Elgaber, Resident

CONTACT

01021708589fatma011124@med.sohag.edu.eg

Ashraf Ahmed Abd El-Latif Abd El-Latif, Lecturer

CONTACT

01021889811

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident of Dermatology and Venereology

Study Record Dates

First Submitted

June 1, 2022

First Posted

June 8, 2022

Study Start

May 1, 2022

Primary Completion

November 1, 2022

Study Completion

January 1, 2023

Last Updated

June 10, 2022

Record last verified: 2022-06

Locations

EG(1)